Drug safety in Crohn's disease therapy.
The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy. Above all the most frequent adverse events and the data on the long-term safety of the therapeutic arsenal available to the physician will be taken into consideration. The drugs described in this article include 5-ASA compounds, antibiotics (metronidazole, ciprofloxacin and rifaximin), corticosteroids (budesonide, prednisone and equivalents), thiopurines (azathioprine and 6-mercaptopurine), methotrexate, anti-tumor necrosis factor inhibitors (infliximab, adalimumab, certolizumab), natalizumab, anticalcineurin inhibitors (cyclosporine, tacrolimus) and mycophenolate mofetil.
Juillerat
Pascal
P
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. pascal.juillerat@chuv.ch
Pittet
Valérie
V
Felley
Christian
C
Mottet
Christian
C
Froehlich
Florian
F
Vader
John-Paul
JP
Gonvers
Jean-Jacques
JJ
Michetti
Pierre
P
D000305:Adrenal Cortex Hormones / Q000592:standards / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000592:standards / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000592:standards / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007166:Immunosuppressive Agents / Q000592:standards / Q000627:therapeutic use*; D012307:Risk Factors; D012449:Safety
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents